Animal models and drug candidates for use in glaucoma filtration surgery: A systematic review. (April 2022)

• Record Type: Journal Article
• Authors: van Mechelen, Ralph J.S.; Wolters, Jarno EJ.; Bertens, Christian J.F.; Webers, Carroll A.B.; van den Biggelaar, Frank J.H.M.; Gorgels, Theo G.M.F.; Beckers, Henny J.M.
• Is Part Of: Experimental eye research. Volume 217(2022)
• Publication Date: 2022-04
• Subjects: Glaucoma -- Glaucoma filtration surgery -- Animal models -- Drugs -- Anti-fibrotic therapy; Ophthalmology -- Periodicals; Eye -- Periodicals; Œil -- Périodiques; Ophthalmology; Periodicals; Electronic journals; 612.8405
• DOI: 10.1016/j.exer.2022.108972
• Languages: English
• ISSNs: 0014-4835

Abstract

Abstract: Glaucoma, a degenerative disease of the optic nerve, is the leading cause of irreversible blindness worldwide. Currently, there is no curative treatment. The only proven treatment is lowering intraocular pressure (IOP), the most important risk factor. Glaucoma filtration surgery (GFS) can effectively lower IOP. However, approximately 10% of all surgeries fail yearly due to excessive wound healing, leading to fibrosis. GFS animal models are commonly used for the development of novel treatment modalities. The aim of the present review was to provide an overview of available animal models and anti-fibrotic drug candidates. MEDLINE and Embase were systematically searched. Manuscripts until September 1st, 2021 were included. Studies that used animal models of GFS were included in this review. Additionally, the snowball method was used to identify other publications which had not been identified through the systematic search. Two hundred articles were included in this manuscript. Small rodents (e.g. mice and rats) are often used to study the fibrotic response after GFS and to test drug candidates. Due to their larger eyes, rabbits are better suited to develop medical devices. Novel drugs aim to inhibit specific pathways, e.g. through the use of modulators, monoclonal antibodies, aqueous suppressants or gene therapy. Although most newly studied drugs offer a higher safety profile compared to antimetabolites, their efficacy is in most cases lower when compared to MMC. Current literature on animal models and potential drug candidates for GFS were summarized in this review. Future research should focus on refining current animal models (for example through the induction of glaucoma prior to undertaking GFS) and standardizing animal research to ensure a higher reproducibility and reliability across different research groups. Lastly, novel therapies need to be further optimized, e.g. by conducting more research on the dosage, administration route, application frequency, the option of creating combination therapies, or the development of drug delivery systems for sustained release of anti-fibrotic medication. Highlights: The strenghts and limitations of an animal model, such as the size of the eye, should be assessed before conducting a study. Standardization of animal research is key to improve reliability and reproducibility across research groups worldwide. Although novel drugs often have a higher safety compared to the gold standard treatment, their efficacy is often lacking. To improve novel therapies, optimization in drug dosage, administration route, and application frequency are needed.